Drug Approval | December 29, 2021
U.S. FDA approves Leo Pharma’s Adbry
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
